Abstract
AbstractA series of highly potent and selective p38 MAP kinase inhibitors is developed originating from a substituted N‐aryl‐6‐pyrimidinone scaffold.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have